Dr. Karl Thomae Gmbh

Karl Thomae Gmbh

Other

Thomas Mueller

Johannes M Weisenberger

Frank Himmelsbach

Helmut Pieper

Guenter Linz

Volkhard Austel

Wolfgang Eisert

Elke Seewaldt-Becker

Gerd Krueger

Armin Heckel

Robert Sauter

Rainer Soyka

Rainer Zimmermann

Klaus Binder

Manfred Psiorz

Volhard Austel

Austel: Volkhard

Austel Volkhard

The invention relates to cyclic urea derivatives of general formula ##STR1## wherein R.sub.a, R.sub.b, X and Y are as defined herein, pharmaceutical compositions containing the derivatives and processes for preparing them.

Cyclic urea derivatives, pharmaceutical compositions containing these

The invention relates to cyclic imino compounds which have, inter alia, valuable pharmacological properties, especially inhibitory effects on cell aggregation, pharmaceutical compositions which contain these compounds and processes for preparing them.

Cyclic imino derivatives and pharmaceutical compositions containing them

Cyclic imino derivatives, processes for preparing them and

Heterobiaryl derivatives

Cyclic imino derivatives of the formula ##STR1## wherein X and R.sub.a to R.sub.g are as defined herein, useful for their inhibitory effects on aggregation, pharmaceutical compositions containing the compounds and processes for preparing them.

Cyclic imino derivatives, pharmaceutical compositions containing these

Cyclic urea derivatives and pharmaceutical compositions containing these

Compounds of the formula ##STR1## wherein X.sub.1 to X.sub.5 are as defined herein, the tautomers, the stereoisomers including the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases. The compounds are useful for inhibiting undesirable cell aggregation.

5-membered heterocyclic compounds, processes for preparing them and

The invention relates to cyclic imino derivatives of general formula

2-pyrrolidinones, pharmaceutical compositions containing these compounds

The invention relates to cyclic imino derivatives of general formula ##STR1## wherein A to G, R.sub.1, Z.sub.1 to Z.sub.6, X and Y are defined as in claim 1, the tautomers, stereoisomers and mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, which have valuable pharmacological properties, preferably aggregation-inhibiting properties, pharmaceutical compositions which contain these compounds and processes for preparing them.

Condensed 5-membered heterocyclic compounds, processes for preparing

Heterobiarly derivatives and pharmaceutical compositions thereof

The invention relates to benzimidazolyl derivatives of general formula ##STR1## wherein R.sub.1 to R.sub.3 are defined as in claim 1, the mixtures of position isomers thereof and the salts thereof, which have valuable pharmacological properties, particularly the effect of extending the thrombin time, a thrombin inhibiting effect and an inhibiting effect on related serine proteases such as trypsin, pharmaceutical compositions containing this compound and processes for the preparation thereof.

Benzimidazolyl derivatives, pharmaceutical compositions containing these

New pyridyl derivatives of the formula ##STR1## wherein R.sub.1 to R.sub.6, A, X and n are as defined herein, the enantiomers thereof, the cis- and trans-isomers thereof if R.sub.4 and R.sub.5 together represent a carbon-carbon bond, and the addition salts thereof. The new pyridyl derivatives have antithrombotic activity and thromboxane-mediated activities. The new compounds are also simultaneously thromboxane antagonists (TRA) and thromboxane synthesis inhibitors (TSH). They also have an effect on PGE.sub.2 -production.

Pyridyl compounds and pharmaceutical compositions containing these

Growing community of inventors

Biberach, Germany

Thomas Mueller